Immune Regulation of COVID-19 Infection in Cancer and Autoimmunity

项目3： 标题：癌症患者对SARS CoV-2免疫的调节 项目负责人：Madhav Dhodapkar和Rafi Ahmed 项目总结： 癌症患者与SARS CoV-2感染有关的发病率和死亡率增加。 然而，新冠肺炎病程在癌症中差异很大的免疫学基础 病人是未知的。除了潜在的癌症相关性免疫性瘫痪外，治疗方法还用于 治疗癌症会进一步增加与COVID相关的病理风险。在这项提案中，我们有 组建了一个多学科团队来解决这些问题。这些研究直接建立在我们之前 在研究病毒感染和癌症免疫方面的专业知识和经验。我们将专注于 尤其是B/浆细胞肿瘤患者接受B/浆细胞去除治疗和 那些接受免疫检查点封锁治疗的肺癌患者。目标1中的研究将评估 治疗性免疫性瘫痪对SARS CoV-2保护性免疫及病毒清除的影响 在B/浆细胞恶性肿瘤患者中。AIM 2的研究将评估抗病毒免疫和 接受免疫检查点阻断治疗的肺癌患者的免疫病理学。AIM中的研究 3将评估B/浆细胞肿瘤患者对SARS CoV-2疫苗的免疫应答 和肺癌，一旦它们被批准并作为标准护理的一部分进行管理。这些研究 不仅提供了对SARS CoV-2保护性免疫的基本见解，而且还提供了必要的 在同时感染SARS CoV-2的情况下，为这些患者提供最佳护理信息。

Project 3: Title: Regulation of SARS CoV-2 immunity in cancer patients Project leaders: Madhav Dhodapkar and Rafi Ahmed Project Summary: Patients with cancer are at increased risk of morbidity and mortality relating to SARS CoV-2 infection. However the immunologic underpinnings of wide variance in COVID-19 disease course in cancer patients are unknown. In addition to underlying cancer associated immune paresis, therapies used to treat cancer can further increase the risk of COVID related pathology. In this proposal, we have assembled a multidisciplinary team to tackle these questions. These studies build directly on our prior expertise and experience in studying immunity in viral infections and cancer. We will focus in particular on patients with B/plasma cell tumors treated with B/plasma cell depleting therapies and those with lung cancer treated with immune checkpoint blockade. Studies in aim 1 will evaluate the impact of therapy-related immune paresis on protective immunity to SARS CoV-2 and viral clearance in patients with B/plasma cell malignancies. Studies in aim 2 will evaluate anti-viral immunity and immunopathology in patients with lung cancer receiving immune checkpoint blockade. Studies in aim 3 will evaluate immunologic responses to SARS CoV-2 vaccines in patients with B/plasma cell tumors and lung cancer once they are approved and administered as a part of standard care. These studies will not only provide basic insights into protective immunity to SARS CoV-2, but also provide essential information for optimal care of these patients in the face of concurrent SARS CoV-2 infection.